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Abstract
Hereditary cerebellar degenerations are a heterogeneous group of diseases often having a detrimental impact on
patients’ quality of life. Unfortunately, no sufficiently effective causal therapy is available for human patients at
present. There are several therapies that have been shown to affect the pathogenetic process and thereby to delay
the progress of the disease in mouse models of cerebellar ataxias. The second experimental therapeutic approach
for hereditary cerebellar ataxias is neurotransplantation. Grafted cells might provide an effect via delivery of a scarce
neurotransmitter, substitution of lost cells if functionally integrated and rescue or trophic support of degenerating
cells. The results of cerebellar transplantation research over the past 30 years are reviewed here and potential
benefits and limitations of neurotransplantation therapy are discussed.
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Background
Hereditary cerebellar ataxias are neurodegenerative
diseases usually having a detrimental impact on patients’
quality of life or even leading to premature death.
Patients suffer from a cerebellar syndrome, also combined
in most of the hereditary ataxias with extracerebellar
neurological symptoms, and in some cases other organ
systems are also affected (for review see [1–5]).
Unfortunately, no sufficiently effective causal therapy
is available for human patients at present (for review see
[6, 7]). Therapy is mostly symptomatic. Common
therapies which can help to delay complete disability in
the patient are rehabilitation and physiotherapy [7].
Pharmacotherapy allows mitigation of some particular
or associated symptoms [6, 7]. Nevertheless, these
therapies do not influence progression of the degener-
ation. Only in some of the ataxias specific treatment is
available. For instance, ataxia with vitamin E deficiency
(AVED) responds to supplementation with vitamin E [8]
and, analogously, autosomal recessive cerebellar ataxia
type 2 (ARCA-2) might potentially be treated with
coenzyme Q10 [9]. In general, there is no therapy which
would be effective to completely stop or prevent
progression of the degeneration or restore lost cerebellar
function in hereditary cerebellar ataxias.
Hereditary ataxias are heterogeneous from the point of
view of the genetics, pathogenesis and manifestations at
both morphological and functional level. In many of
them, the molecular mechanisms of pathogenesis are
not known. Thus, development of causal therapy is diffi-
cult and there might not be any universal approach
applicable for all of them. Several experimental studies
in laboratory animals have already succeeded in target-
ing pathogenetic processes, and neurotransplantation
research has also shown some promising results (for
overview see Table 1). Nevertheless, these therapies are
still under investigation and none of these approaches
has yet become a routine method for human therapy.
Such research, however, did not aim only to contribute
to development of potential therapies but also to
improve knowledge about the pathogenesis of hereditary
ataxias. The results of cerebellar transplantation research
over the past 30 years will be reviewed here.
Experimental therapeutic approaches targeting
pathogenetic processes
For experimental investigation of potential therapies for
hereditary degenerative cerebellar ataxias, as well as of
their pathogenesis, cerebellar mutant mice have been
widely used. There are numerous spontaneous mutants
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as well as transgenic mouse models of particular human
diseases, both having some advantages and also limita-
tions for their use and for translation of the findings into
human medicine (for review see [10]).
Intervention into the pathogenic process seems to be
an optimal strategy since it could theoretically prevent
or delay development of degeneration and improve the
functionality of remaining cells, if started in time.
Table 1 Experimental therapeutic approaches for cerebellar degenerations
Therapy Subject Effect References
Inhibition of mutated gene expression SCA3 mice -clearance of nuclear accumulation of ataxin-3-improved
motor performance-alleviation of neuropathological changes
[14]
-suppression of already manifested symptoms [11]
SCA7 mice -reduction of ataxin-7 aggregation-improved motor
performance-prevention of synaptic loss between
climbing fibers and Purkinje cells
[13]
Enhancement of pathological protein
elimination
SCA3 mice -decrease of ataxin-3 accumulation-suppression of
pontine neuronal death-improved motor performance
[15]
SCA7 mice -reduction of ataxin-7 intranuclear inclusions-improved
motor performance
[12]
Stabilization of calcium signaling SCA2, SCA3 mice -alleviation of neuronal cell loss-improved
motor performance
[17, 18]
Transcranial direct current stimulation Human patients -neuromodulation of the cerebellum [19]
Embryonic (fetal) neural tissue transplantation pcd mice -colonization of the host molecular layer [31–33, 35, 38]
-improved motor performance [40, 41]
Lurcher mice -organotypic organization of the graft, colonization of the
host molecular layer
[54, 58, 59]
-mild improvement of gait [57]
Weaver mice -organotypic organization of the graft-colonization of the
host cerebellum with granule-like cells
[64, 65]
SCA1 mice -improved motor performance [80]
Neural precursor transplantation Nervous mice -support and rescue of host’s Purkinje cells-reduction




Meander tail mice -replenishment of deficient granule cell population [76]
SCA1 mice -increased survival of Purkinje cells-improved motor
performance
[81]





-lengthened their life span without influencing the decline
of motor performance
[92]





-alleviation of neuropathological changes without
influencing the decline of motor performance
[86]
Embryonic stem cell, embryonic stem
cell-derived neural precursor transplantation
Weaver mice -no adoption of region-specific cell identities [67]
Harlequin mice -induction of endogenous neuronal precursor
proliferation-delayed onset of the ataxia
[79]
Mesenchymal stem cell transplantation Lurcher mice -increased Purkinje cell survival-improved
motor performance
[60]
SCA1 mice -mitigated cerebellar disorganization-improved
motor performance
[82]





-reduced astrocytic and microglial activation-increased
Purkinje cell survival-improved motor performance
[87–90]
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Several experimental studies targeting pathogenic pro-
cesses have been done in transgenic mouse models
carrying the human pathological allele causing cere-
bellar degeneration. These studies have shown not
only a potential direction for the development of a
specific therapeutic method but also confirmed the
role of particular mechanisms in pathogenesis of the
diseases [11–15].
In some hereditary cerebellar degenerations, a noxious
effect of accumulated abnormal protein which is more
resistant to proteolytic degradation is expected. Thus,
silencing of the mutated gene’s expression might be
helpful. In a mouse model of spinocerebellar ataxia type
3 (SCA3), halting the expression of ataxin-3 cleared
nuclear accumulation of the abnormal protein in SCA3
mice [16]. Silencing of the expression of mutant ataxin-3
started after disease onset alleviated motor impairments
as well as neuropathological changes [14]. Boy et al. [11]
showed that turning off the expression of ataxin-3 at an
early stage of the disease can even completely reverse
already manifested symptoms in the mice. Similarly, in
SCA7 mice, suppression of mutant allele expression by
50 %, started one month after the onset of ataxia, was
effective at halting or even reversing motor symptoms,
reducing mutant ataxin-7 aggregation in Purkinje cells
and preventing synaptic loss between climbing fibers
and Purkinje cells [13].
Another possibility is to enhance elimination of the
pathological protein. Stimulation of proteasome activ-
ity by Rho-kinase, promoting mutant ataxin-3 degrad-
ation, alleviated the neurological phenotype in SCA3
mice [15]. Treatment with interferon beta reduced
mutant ataxin-7 in intranuclear inclusions and led to
improvement of balance and motor coordination in
SCA7 mice [12].
Mutant ataxin-2 and ataxin-3 with expanded poly-
glutamine tracts have been shown to interact spe-
cifically with type 1 inositol 1,4,5-trisphosphate
receptor (InsP3R1), an intracellular calcium (Ca2+)
release channel, and sensitize it to activation [17, 18].
Treatment with dantrolene, a calcium ion stabilizer,
alleviated motor deficits and neuronal cell loss in
SCA2 and SCA3 transgenic mouse models [17, 18].
These findings suggest that disturbed calcium
signaling may play a role in the pathogenesis of SCA2
and SCA3 [17, 18].
Recently, the possible therapeutic potential of non-
invasive cerebellar stimulation with transcranial magnetic
stimulation or transcranial direct current stimulation has
been discussed [19, 20]. The stimulation is capable of
influencing various cerebellar functions and thus it might
become an applicable rehabilitation strategy; nevertheless,
further studies are still necessary to validate this thera-
peutic approach [20].
Taken together, it has been shown in mouse models of
hereditary cerebellar degeneration that it is possible to
suppress the degenerative process and thereby prevent
or delay irreversible neuropathological changes and to
improve or stimulate residual cerebellar function. Some
of these methods are based on genetic modifications and
thus require a thorough assessment of potential risks
prior to application in humans. Others are based just on
drug administration and are therefore more easily
acceptable to patients. The problem of these approaches,
however, is that they cannot solve advanced cell loss and
thus they would probably be ineffective in functional
recovery when severe cell loss has already occurred.
Neurotransplantation therapy, on the other hand, aims
primarily to restore cerebellar function by substitution
of cells that have been already lost rather than to pre-
vent damage of the cerebellum. Nevertheless, it has
subsequently been shown that it can take effect in
various ways.
Neurotransplantation in cerebellar mutant mice
Cerebellar transplantation has been investigated inten-
sively for a long time using ataxic mice, both spontaneous
mutants and transgenic models. Beneficial effects have
been shown in some cases. Nevertheless, some findings
are controversial and by now it is not clear whether
neurotransplantation could become a routine therapy for
cerebellar degeneration in humans, and there are still
serious limitations. The problems of stem cell- and
neurotransplantation-based therapy have already been
reviewed by Rossi and Cattaneo in 2002 [21]. Most of the
issues they pointed out, however, persist to this day.
For experimental neurotransplantation, various types
of cell can be used: embryonic (fetal) neural tissue,
embryonic (fetal) or adult neural stem cells, embryonic
stem cells, adult stem cells, mesenchymal stem cells
isolated from various tissues (e.g. bone marrow, adipose
tissue), and carcinoma stem cells that are considered as
dangerous for the risk of tumorigenesis. All these cells
have some advantages and disadvantages dealing with
biological as well as ethical aspects, which would
become of much higher importance in humans. These
various grafts have been transplanted into various
cerebellar mutant mice and thus we have many but not
all pieces of a large and diverse mosaic.
Purkinje cell degeneration (pcd) mice suffering from
almost complete loss of Purkinje cells, slowly progressive
granule cell degeneration, moderate reduction of cere-
bellar nuclei and some extracerebellar disorders [22–29]
have been shown to be a good model for neurotrans-
plantation research and they were also used for
pioneering studies by the teams of Constatino Sotelo
[30–36] and Lazaros C. Triarhou [37–41]. In these mice,
solid embryonic cerebellar grafts formed a characteristic
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three-layered organization with the presence of parallel
fibers which were, however, not oriented in a parallel
fashion and were reduced in number compared with the
normal cerebellar cortex [37]. Grafted Purkinje cells
were able to migrate from the solid embryonic cerebellar
graft, and cells from both solid and dissociated grafts
colonized the host molecular layer, albeit being localized
also in its superficial parts [31–33, 35, 38]. Sotelo and
Alvarado-Mallart [33] reported that such neuronal inva-
sion is a selective process since only Purkinje cells were
able to penetrate into the molecular layer of the host cere-
bellum. They have also suggested that the deficient mo-
lecular layer of pcd mice exerts a selective neurotrophic
effect on neurons of the missing category, and that the
embryonic neurons are able to respond to these signals
[32]. Carletti and Rossi [42] also found that the pcd cere-
bellum provides signals inducing selective mechanisms
that favor the survival of donor Purkinje cells.
Grafted Purkinje cells synaptically integrated within the
host cerebellar cortex, having synaptic contacts like nor-
mal Purkinje cells but lacking basket fiber-pinceau forma-
tions around the initial segment of the axon [30, 33, 35].
Intracellular recordings from grafted Purkinje cells located
in the molecular layer revealed normal bioelectrical prop-
erties and demonstrated that grafted cells responded to
stimulation mediated through both climbing and mossy
fibers as well as to inhibitory signals [34]. On the other
hand, Rosenfeld et al. [43] reported that grafted cells
formed normal cerebellar cytoarchitecture only with other
grafted cells and not with the cells of the cerebellum of
host pcd mice. Furthermore, re-establishment of the corti-
conuclear projections in pcd mice is problematic [35]. The
granule cell layer has been shown to prevent grafted cells
from migrating and their axons from growing toward the
deep cerebellar nuclei [44]. Thus, proximity of the cerebel-
lar nuclei is necessary to establish projections of grafted
Purkinje cells to the nuclei [31, 39, 45] since Purkinje cells
localized in their normal position at the border of the
granule and molecular layer have a limited possibility
of contacting the cerebellar nuclei [44]. Triarhou et
al. [39] reported that, if grafted onto the deep cere-
bellar nuclei, Purkinje cells are capable of forming
axonal contacts in the cerebellar nuclei and then of
moving to the cortical locality. In pcd mice, Sotelo et
al. [36] showed that, for grafted Purkinje cell radial
migration, the host’s Bergmann fibers were occupied
and that grafted embryonic Purkinje cells can trigger
molecular changes in the Bergmann fibers necessary
for their migration.
Bilateral transplantation of a fetal cerebellar cell suspen-
sion into the deep cerebellar nuclei partially restored
corticonuclear projections in the cerebellum and im-
proved motor coordination and increased locomotor
activity of pcd mice [40, 41].
Intravenous injection of bone marrow-derived cells at the
age of 20 days led to reduction of the degenerative process
in the olfactory bulb and improvement of olfaction in pcd
mice, but did not change the degeneration of cerebellar
Purkinje cells [46].
Lurcher mutant mice lose virtually all Purkinje cells
and their granule cells, other cerebellar cortex interneu-
rons and inferior olive neurons are substantially reduced
as a secondary consequence, while cerebellar nuclei are
less affected [47–51]. Primary degeneration of Purkinje
cells is caused by the Grid2Lc mutation in the δ2 glutam-
ate receptor (GluRδ2) encoding gene [52]. GluRδ2
receptors are expressed at high levels in cerebellar
Purkinje cell bodies and dendrites and are important for
function of their synapses within the molecular layer
[53]. The Grid2Lc mutation is a gain of function muta-
tion, which changes the receptor into a leaky membrane
channel that chronically depolarizes the cells inducing
their degeneration [52].
In these mice, embryonic cerebellar grafts have been
also studied several times. Tomey and Heckroth [54],
who grafted a cerebellar cell suspension, reported 50 %
graft survival in both young and adult Lurcher mice.
Later cell suspension and solid cerebellar graft survival
over 60 % has been found two and six months after
transplantation in Lurchers and the survival rates were
comparable to those in wild type mice [55–57]. Aggre-
gates of grafted cells with organotypic organization on
the surface of the host cerebellum and invasion of
grafted cells into the host’s molecular layer have been
observed [54, 58, 59]. Nevertheless, migration of grafted
cells or fiber sprouting to locations distal from the
engrafting place, e.g. to the cerebellar nuclei, were rare
in Lurchers [56, 57]. Timely transplantation of normal
embryonic Purkinje cells can prevent secondary degen-
eration of cerebellar granule cells and inferior olive
neurons, and this provides evidence for the secondary
nature of degeneration in these cell categories and indi-
cates at least some level of integration of the graft within
the host cerebellar cortex [59]. Only a mild effect of
embryonic cerebellar cell suspension on gait parameters,
insufficient from a therapeutic point of view, has been
observed in adult Lurcher mice [57].
A significant improvement in performance on motor
tests was observed by Jones et al. [60] after transplant-
ation of mesenchymal stem cells into the cerebellum of
newborn Lurcher mice. Donor cells were located adja-
cent to the Purkinje cell layer and produced neuro-
trophic factors (BDNF, NT-3 and GDNF) that increased
Purkinje cell survival [60]. The question, however, is
whether the Lurcher Purkinje cells, still having their
mutated δ2 receptor [52], are fully functional and
whether their survival is the sole reason for the functional
effect of the transplantation.
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Weaver mice carry the missense GrikWv mutation of
the gene encoding a G-protein coupled with inward
rectifying potassium channel [61]. They suffer from
disorganization of granule layer development and degen-
eration of cerebellar granule cells [62, 63]. In Weaver
mice, dissociated embryonic cerebellar cells grafted onto
the cerebellum developed into a large mass of tissue
with a trilaminar organization [64–66]. Grafted granule-
like cells proliferated, migrated from the place of trans-
plantation and were able to develop synaptic contacts in
the Weaver mutant cerebellum [64–66].
In Weaver mutant mice, grafted cerebellar-derived
multipotent astrocytic stem cells and embryonic stem
cell-derived neural precursors were not capable of
adopting region-specific cell identities, but the milieu
of the granuloprival host cerebellum provided signals
slightly supporting neuronal differentiation of donor
cells [67].
Nervous mutant mice are characterized by mitochon-
drial abnormalities and degeneration of Purkinje cells
[68]. The degeneration is mediated by tissue plasmino-
gen activator, levels of which are elevated in the cerebel-
lum of homozygous Nervous mice [69, 70]. Li et al. [71]
have shown that undifferentiated neural stem cells
grafted into the cerebellar cortex of newborn Nervous
mice contacted the host’s Purkinje cells and supported
their mitochondrial function, dendritic growth and syn-
aptogenesis, rescued the cells from degeneration and
improved motor coordination. Also, in organotypic slices
of Nervous cerebellum, more Purkinje cells survived
when cocultured with neural stem cells in vitro [71].
The rescue of Purkinje cells was related to reduction of
the excessive tissue plasminogen activator level mediated
by the neural stem cell-induced rectification of tissue
plasminogen activator gene expression [71]. Thus, in this
case, grafted cells modulated the pathogenetic pathway
of Purkinje cell degeneration. Rescue of Purkinje cells
and motor performance by grafted neural stem cells that
did not fully differentiate into neurons but formed gap
junctions with the host’s cells have also been reported in
Nervous mice by Jaderstad et al. [72].
Meander tail mice are recessive mutants showing
ankylosis or fusion of tail vertebrae [73] and defective
development of the cerebellum resulting in abnormal
arrangement of cerebellar lobes, reduced number of
granule cells, random positioning of Purkinje cells and
disorganized spinocerebellar projection, most evident in
the anterior lobes [74, 75]. Rosario et al. [76] grafted
multipotent neural progenitor cells isolated from the
external granular layer of the cerebellum of newborn
wild type mice into the granuloprival area of the cerebel-
lum of newborn Meander tail mice. Most of the grafted
cells differentiated into granule cells and thus partially
replenished the deficient neuronal population [76]. In
this case, donor neural stem cells were derived from a
structure which is the natural source of the cell type that
had to be substituted and the donor was of the same
ontogenetic period as the host. Nevertheless, some
factors that theoretically force the progenitors to have a
potential for multiple fates to differentiate toward the
repletion of deficient cell types might be supposed [76].
Harlequin mutant mice are a model of oxidative
stress-mediated cerebellar degeneration and ataxia
[77, 78]. Human embryonic stem cell-derived progeni-
tors of cerebellar granule cells grafted into the cere-
bellum of Harlequin mice survived only for several
weeks, but induced proliferation of endogenous neuronal
precursors in the leptomeninges that crossed the molecu-
lar layer and differentiated into mature neurons [79]. Fur-
thermore, the treatment preserved granular and Purkinje
cell layers and delayed onset of the ataxia as measured
with the rotarod test [79].
Several strains of transgenic mice serve as models of
particular human autosomal dominant spinocerebellar
ataxias (SCAs). In SCA1 mice, a transgenic mouse
model of human spinocerebellar ataxia type 1, trans-
plantation of an embryonic cerebellar cell suspension at
the time of ataxia onset led to improvement in motor
function as compared with sham-operated controls [80].
The grafts were found in various locations, some intra-
parenchymally while others formed extraparenchymal
structures [80]. Nevertheless, most of the grafts survived
for up to 20 weeks after engraftment and contained
donor-derived Purkinje cells [80].
Chintawar et al. [81] grafted neural precursor cells into
the cerebellar white matter of SCA1 mice at the age of
absent, initial and significant Purkinje cell loss. Only in
mice with significant degeneration did grafted cells mi-
grate into the cerebellar cortex and the treatment lead
to improvement of motor skills [81]. Despite grafted
cells not adopting the Purkinje cell phenotype, the cere-
bellar cortex of treated mice contained more surviving
Purkinje cells which, contrary to those in sham-operated
SCA1 mice, showed normalization of membrane poten-
tial [81]. Since no marked increase in levels of neuro-
trophic factors had been detected, Chintawar et al. [81]
suggested that the protective effect of grafted neuropro-
genitor cells on host Purkinje neurons was mediated
rather by direct contact between grafted and host cells.
Similar findings were reported by Jaderstad et al. [72].
Intrathecal injection of mesenchymal stem cells mitigated
cerebellar disorganization, suppressed atrophy of Purkinje
cell dendrites and normalized motor coordination deficits
in SCA1 mice [82].
Chang et al. [83] investigated the effect of intravenous
(via the tail vein) or intracranial (via the occipital
foramen magnum) injection of human mesenchymal
stem cells in SCA2 transgenic mice. After intravenous
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injection, grafted cells were detected in the cerebellar
white matter, molecular layer, in the lumen of blood
vessels in the white matter and in the cerebral cortex
[83]. In mice treated this way, increased survival of host
Purkinje cells, delayed onset of disease and improved
motor function has been observed [83]. In the case of
intracranial injection, grafted cells were seen only in a few
lumens of blood vessels, but not inside the cerebellar tis-
sue, and this approach failed to achieve the neuroprotec-
tive effect observed after intravenous administration [83].
SCA3 (Machado-Joseph disease) is a polyglutamine
disorder in pathogenesis of which inflammatory pro-
cesses play a role [84]. In a mouse model of SCA3,
cerebellar neural stem cells isolated from neonatal wild
type mice and cultured and differentiated in vitro were
transplanted into the cerebellum [85]. Grafted neural
stem cells differentiated into astrocytes and oligodendro-
cytes as well as into functional neurons [85]. The treat-
ment alleviated motor impairment, reduced Purkinje cell
loss, granular layer atrophy and mutant ataxin-3 aggre-
gates [85]. The transplantation has been also suggested to
suppress neuroinflammation since it reduced the levels of
inflammatory modulators interleukin-1b, interleukin-6
and tumor necrosis factor α in SCA3 mice [85]. Further-
more, the transplantation induced elevation of BDNF level
in these mice [85].
Niemann-Pick disease is an autosomal recessive lyso-
somal storage disease with accumulation of sphingomye-
lin in many tissues. Niemann-Pick disease type C is a
defect of sphingomyelin transport and typically affects
the cerebellum. Niemann-Pick disease types A and B are
caused by defects of sphingomyelinase enzyme. Unlike
human patients, Niemann-Pick type A mice suffer from
progressive degeneration of Purkinje cells in the cerebellum
and develop ataxia [86].
In a mouse model of Niemann-Pick disease type C,
therapy with mesenchymal stem cells has been tested
with promising results [87–89]. Bone marrow-derived
mesenchymal stem cell transplantation reduced astro-
cytic and microglial activation in the cerebellum of these
mice [87], led to an increase in Purkinje cell numbers
and improved motor skills [88]. It has been shown that
electrically active Purkinje neurons originated from
existing Purkinje cells through fusion-like events with
grafted mesenchymal stem cells [88]. Lee et al. [90] showed
that bone marrow-derived mesenchymal stem cells pro-
mote the survival of Purkinje cells in Niemann-Pick disease
type C mice by correction of the altered calcium homeosta-
sis, modulation of sphingolipid metabolism and by inhib-
ition of apoptotic pathways. Also, transplantation of
adipose tissue-derived stem cells rescued Purkinje
neurons, alleviated inflammatory responses and re-
stored motor coordination in Niemann-Pick disease
type C mice [89].
In a mouse model of Niemann-Pick disease, bone
marrow-derived cells were also used for ex vivo gene
therapy [91]. Normal murine bone marrow cells were
genetically modified to overproduce human acid sphin-
gomyelinase, the enzyme which is defective in Niemann-
Pick disease types A and B, and were injected intraven-
ously at the age of 3 days and intracerebrally at 4 weeks
to sphingomyelinase-deficient mice [91]. The treatment
led to transient normalization of enzyme activity and
reduction of sphingomyelin in the tissues, suppression
of Purkinje cell degeneration and normalization of
cerebellar function [91].
Injection of neural stem cells into the cerebellum of
Niemann-Pick disease type C1 mice lengthened their life
span, but did not influence the decline of motor per-
formance as measured by the rotarod test [92]. Similarly,
transplantation of human neural stem cells into neonatal
mice with targeted deletion of the sphingomyelinase
gene, a model of Niemann-Pick type A, did not prevent
Purkinje cell loss or decline in rotarod performance,
despite reduction of histopathological changes that were
even more widespread than the distribution of grafted
neural stem cells [86]. On the other hand, Lee et al. [93]
reported alleviation of neuropathological features, an
increase of surviving Purkinje cells and enhancement of
neuronal networks with functional synaptic transmission
in Niemann-Pick disease type C mice treated with intra-
cerebellar injection of conditionally immortalized neural
stem cells of hippocampal origin.
Mechanisms of the effect of the grafts
Experiments in models of neurological diseases includ-
ing cerebellar degeneration have shown that grafts can
employ their effects via various mechanisms. One
relatively simple way is delivery of a scarce neurotrans-
mitter. The most successful neurotransplantation ther-
apy used in human patients is that for Parkinson’s
disease. Rossi and Cattaneo [21] pointed out that in this
case dopaminergic neurons of the substantia nigra are
grafted directly onto the striatum which is the target
structure for the dopaminergic projection, and that para-
crine release of dopamine is sufficient to restore function
without the need to reestablish specific cell-to-cell
projections. Furthermore, fetal substantia nigra directly
provides the desired cell phenotype. Thus the nature of
Parkinson’s disease represents an optimal situation to be
solved by substitution of lost neurons since the task of
the graft is just to deliver an adequate amount of a
neurotransmitter, in this case dopamine.
Theoretically, complete substitution of lost cells and
precise reconnection of neural circuitry by grafted cells
would be optimal, since it would completely restore
normal structure and function. However, this is probably
the most difficult endpoint to achieve since it requires
Cendelin Cerebellum & Ataxias  (2016) 3:7 Page 6 of 11
sufficient numbers of surviving grafted cells, migration
into appropriate positions, differentiation into appropri-
ate cell types, fiber sprouting and establishment of
precise cell-to-cell connections (for review see [21]). The
cerebellum represents a structure for which specific
topographically arranged projections with other struc-
tures, but also connections within the cerebellar cortex
as well as corticonuclear projections, are essential for its
function [21]. A good source of cerebellar cell phenotypes
to substitute lost cells is embryonic (fetal) cerebellar tissue
[31–33, 35, 38, 56, 58, 65, 80, 94]. Nevertheless, functional
integration of this kind of graft is not easy (see above).
Neural precursors, on the other hand, have mostly
been shown to fail in adopting the specific cerebellar
phenotypes to be substituted or in completing neur-
onal differentiation at all [71, 72, 81, 86] despite the
fact that they are able to migrate into the cerebellum
even after injection into the lateral ventricle [95]. The
differentiation of these cells might depend on both
the local niche and their origin. For instance, Klein et
al. [96] showed that neural stem cells from the fore-
brain and the cerebellum fail to generate neurons
when grafted ectopically, but neural stem cells of
cerebellar origin acquired features of cerebellar gran-
ule cells when grafted onto the perinatal cerebellum.
Also, adult highly purified hematopoietic cells have
been shown to fail to transdifferentiate into neurons
when injected into the normal mouse cerebellum
[97]. On the other hand, small number of donor
derived Purkinje cells has been found in the cerebel-
lum of mice 15 months after intravenous injection of
bone marrow-derived cells [98] (see also below).
Many studies have shown that grafts can provide a
neuroprotective effect, trophic or metabolic support
for degenerating cells, or modulate the inflammatory
response participating in cerebellar damage. In this way
the graft may rescue the cells or delay degeneration if
applied before the changes become irreversible. These
effects have been suggested mainly in mesenchymal stem
cells that have been shown to produce neurotrophic
factors rescuing degenerating Purkinje cells [60] and to
modulate glial activation, inflammation and apoptosis
activation [87, 89, 90]. Neural precursors have been
suggested to prevent degeneration of the host’s Purkinje
cells by making direct contact with them, mediating
metabolic or trophic support [71, 81]. Jaderstad et al.
[72] demonstrated the importance of gap junctions for
interactions between grafted neural stem cells and host
Purkinje cells. They found that functional gap junctions
were formed between grafted neural stem cells and host
cells at risk in Nervous and SCA1 mice [72]. Gap
junction formation was associated with rescue of
Purkinje cells from degeneration and with improvement
of motor performance, and these beneficial effects of
neural stem cells were abrogated when formation or
function of the gap junctions was inhibited [72].
Grafted bone marrow-derived cells have been shown
to give origin to Purkinje cells [98, 99] which in some
cases have arisen from cell fusion between the grafted
cells and host Purkinje cells [100, 101]. Fusion-like pro-
cesses may rescue Purkinje cells from degeneration [88].
On the other hand, Nern et al. [102] suggested that fusion
of hematopoietic cells with Purkinje cells is only a transient
phenomenon and does not establish stable heterocaryons
under physiological conditions. Nevertheless, the frequency
of fusion between bone marrow-derived cells and Purkinje
neurons can be increased by pathological processes, e.g.
inflammation or mild degeneration [101–103].
Mesenchymal stem cells have also been used as a tool
for ex vivo gene therapy in a mouse model of Niemann-
Pick disease [91, 104]. Normal, genetically unmodified
neural stem cells even rectified abnormal gene expression
thereby disrupting the pathogenetic process [71].
The cerebellum can be also affected by demyelinating
processes. In this case, transplantation of cells providing
remyelination might be helpful. In a rat model of
radiation-induced demyelination causing cognitive and
motor coordination impairments, injection of human
embryonic stem cell-derived oligodendrocyte progenitors
into the central cerebellar white matter led to remyelina-
tion and improved motor coordination measured using
the rotarod test [105].
Conclusion
Several clinical studies have reported successful use of
cerebellar transplantation or systemic administration of
stem cells in degenerative diseases that affect the cere-
bellum in humans [106–108]. Donor-derived astrocytes
as well as neurons including Purkinje cells have been
found in the cerebella of patients after bone marrow
transplantation [99, 109]. Nevertheless, this approach is
still rather in the stage of experiments in laboratory
animals, and reliable evidence for long-persisting effi-
ciency and safety of neurotransplantation therapy for
hereditary ataxias is still missing. A donor-derived brain
tumor that developed from grafted neural stem cells has
been reported in a patient with ataxia telangiectasia
[110]. Prior to routine use of cerebellar transplantation
in human patients, if it will ever be possible, it would be
necessary to answer many questions regarding the long-
term efficiency of the therapy and also its safety.
Proliferation, migration, differentiation and fiber sprout-
ing of grafted cells that are necessary for cell replacement
and full functional integration strongly depend not only on
the properties of the cells but also on the host tissue niche.
Neurogenic features of the host tissue are determined by
normal features of the tissue, in particular brain structure,
and by pathological changes of the diseased tissue. Some
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factors, like lack of a certain cell type, might promote
appropriate development of the graft, while others could
have a negative effect, limiting neuronal differentiation and
integration of grafted cells (for review see [21]). The task
for future research is elucidating all important factors
which play a role in determination of the graft’s fate in
particular diseases. Knowing these factors can help to
predict the particular diseases in which neurotransplanta-
tion could be effective or to develop therapeutic interven-
tions to make the host tissue niche more favorable for the
development and functional integration of the graft.
The most effective source of cells having determined
specific cerebellar phenotypes is embryonic cerebellar
tissue. These cells have to be harvested from embryos
and they cannot be expanded in vitro to sufficient
amounts. Thus, obtaining grafts for clinical use would
be problematic from an ethical point of view as well as
that of quality and quantity. Nevertheless, it has been
shown that induction of differentiation of embryonic
stem cells into cerebellar Purkinje cells and granule cell
precursors is also possible [111]. Since long-term and in-
tensive proliferation of embryonic stem cells in vitro is
easy, they could be a more acceptable type of graft if
their efficient cerebellar differentiation in vivo could be
induced. Adult stem cells obtained from various tissues
would be an ethically acceptable material for transplant-
ation therapy and, again, the technique of massive differ-
entiation into cerebellar cell phenotypes has to be
developed. Neuronal differentiation might be easier in
neural stem cells. Neural stem cells isolated from the
postnatal cerebellum and expanded in vitro as neuro-
spheres have been shown to differentiate into astrocytes,
oligodendrocytes as well as neurons after transplantation
into the cerebellum in the form of single neurosphere
[112]. When cultured as neurospheres they enable en-
graftment in the form of single cell suspension or solid
neurospheres containing more cells and being analogy of
solid embryonic grafts that might be more resistant to
detrimental effects of non-neurogenic niche in the
pathologically changed cerebellar tissue. Unlike many
adult stem cells neural stem cells cannot be obtained
without ethical problems. Another research task is to
find optimal methods of nerve fiber guidance that would
promote reconstruction of neural circuitry. Up to now,
mesenchymal stem cell transplantation seems to be quite
effective in rescuing degenerating neurons in cerebellar
mutant mice. Nevertheless, this kind of therapy has to
be applied in time. Early diagnosis based on genetic test-
ing of family members helps in this regard.
Beyond the investigation of therapeutic approaches for
neurological diseases, neurotransplantation also remains a
tool for studying the mechanisms and factors playing a
role in brain development, cell differentiation and migra-
tion, and neural plasticity and regeneration [96, 113].
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